July 14, 2022 11:08 AM EDT

Ultragenyx sells $500M in royalty interest on rare disease drug to Canadian pension plan

Kyle LaHucik

Senior Reporter

Ultragenyx said early Thursday it has sold 30% of its royalty interest from Kyowa Kirin on future sales of the companies’ rare disease drug Crysvita …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ultragenyx sells $500M in royalty interest on rare disease drug to Canadian pension plan

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Upcoming PDUFA dates may be ensnared by Trump's pause at HHS, analyst says

With Sam Altman’s help, Retro Biosciences eyes $1B to extend lifespan by 10 years

Merck and Eisai reveal late-stage fail for Keytruda and Lenvima in gastroesophageal cancer

The crucial obesity data to watch for this year

Novo Nordisk’s amycretin prompts 22% weight loss in early obesity trial

Fueling More Breakthroughs: Manufacturing Innovation to Expand Gene Therapy’s Reach

Ul­tragenyx sells $500M in roy­al­ty in­ter­est on rare dis­ease drug to Cana­di­an pen­sion plan

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Ultragenyx sells $500M in royalty interest on rare disease drug to Canadian pension plan